Aditi R Saxena

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Placebo Controlled

Top Venues

Diabetes, obesity & metabolism

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Clare Buckeridge, Nikolaos Tsamandouras, Santos Carvajal-Gonzalez, Lisa S Brown, Martha Hernandez-Illas, Aditi R Saxena
Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies. Diabetes, obesity & metabolism 26 (8) (2024)
Clare Buckeridge, Nikolaos Tsamandouras, Santos Carvajal-Gonzalez, Lisa S Brown, Martha Hernandez-Illas, Aditi R Saxena
Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies. Diabetes, obesity & metabolism (2024)
Aditi R Saxena, Juan P Frias, Donal N Gorman, Rene N Lopez, Nabil Andrawis, Nikolaos Tsamandouras, Morris J Birnbaum
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes. Diabetes, obesity & metabolism (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism 25 (4) (2023)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism (2022)
Aditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P Esler, Albert M Kim
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism (2022)
Aditi R Saxena, Donal N Gorman, Ryan M Esquejo, Arthur Bergman, Kristin Chidsey, Clare Buckeridge, David A Griffith, Albert M Kim
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nature medicine 27 (6) (2021)